Randy Baron
Lead Portfolio Managee, Pinnacle Associates
Randy joined Pinnacle Associates in 2012 and serves as lead Portfolio Manager of the firm’s various international and global products and is responsible for the firm’s overall international investment strategy. In the first quarter of 2019, the International Small Cap strategy he manages was ranked among the top 10 ten players in its respective universe. In the second quarter of 2020, he was the #1 ranked manager globally among international small cap funds with an overall quarterly return of over 56%. He was also up 80% in the first quarter of 2021. He is additionally responsible for Pinnacle’s Turnaround strategy, which subscribes to the thesis that sometimes high-quality businesses fall (temporarily) out of favor, plus serves as a member of the investment committee for the firm’s All-Cap strategy. Previously, Randy was Senior Securities Analyst at SM Investors, an investment partnership in New York, where his responsibilities included security analysis in various industries encompassing wireless telephony, cable television, food, and publishing. Before SM Investors, he worked at JP Morgan and Lazard Freres. Baron’s experience also encompasses an early role alongside Gabelli Asset Management, which is known for its stock-picking expertise. Randy received a B.A. in international studies with a concentration in economics from Johns Hopkins University. He earned his M.A., with highest honors, from Hopkins’ Paul H. Nitze School of Advanced International Studies, where his course of study focused dually on International Economics and Latin American studies.

Jonathan Saxon
Managing Director; Head of International Equity Sales - US, Stifel
Jon Saxon has over twenty-five years of experience marketing international equities into the US institutional investor sector.   He began his career at Credit Agricole Cheuvreux in 2000 as a European equity salesperson. In 2006, he joined Kepler Capital Markets as Head of Equities. Jon opened Berenberg Capital Market’s New York office in 2012 and joined Stifel in 2016 to manage and build their European equities platform in the US. He has successfully generated and completed many capital raises, corporate roadshows, international site visits, and conferences. Prior to his experience in international equities, Jon worked at Goldman Sachs Asset Management in New York.  He has traveled globally for work and pleasure. Jon lives in Westport, CT and graduated from the University of Pennsylvania in 1994.  

Nicholas Moore
Managing Director, Healthcare Investment Banking, Stifel
Nicholas has over 20 years’ experience in the Healthcare industry, having originally trained as a medical doctor at Cambridge University and Harvard Medical School, following an undergraduate degree in Medical Sciences with a focus on immunology also at Cambridge. He joined Morgan Stanley’s Healthcare Investment Banking Team in 2006, where he worked on a number of M&A and capital markets transactions. In early 2011, Nicholas moved to the Equity Capital Markets team at Jefferies in London, where he initially focused on raising equity capital across industries within the broader EMEA region. In December 2013, Nicholas was named as one of the Top 40 Under 40 Rising Stars in Investment Banking by Financial News, partly in recognition of the more than 20 equity capital markets transactions he completed in 2013 alone. Since mid-2013, Nicholas focused on raising equity capital for European healthcare companies, especially those companies in the biopharma subsector targeting investment from U.S.-based healthcare specialist investors. In January 2018, Nicholas moved to Stifel as a Managing Director on the Healthcare Investment Banking team to continue to focus on delivering equity financing solutions to Europe-based healthcare companies, but also with a broader remit across M&A and strategic advice. Nicholas has an especially busy practice helping US companies IPO and raise money on LSE AIM and currently serves as Corporate Broker to companies such as Renalytix (Utah and New York-based), MaxCyte (Maryland-based) and Polarean Imaging (North Carolina-based) as well as helping UK and European companies IPO or dual list on the NASDAQ exchange.

James McCullough
CEO, RenalytixAI
James is Renalytix AI’s Chief Executive Officer, with primary focus on strategic planning and execution, as well as coordination with key stakeholders. James has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. His skills include equity and debt capital formation, strategic development and partnerships, executive team structuring, regulatory issues and marketing. James was most recently chief executive officer of Exosome Diagnostics, a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer. Exosome Diagnostics has recently been acquired by Bio-Techne Corporation (NASDAQ: TECH). James is also a managing partner of Renwick Capital, LLC (“Renwick”), a management consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. James received his B.A. from Boston University and an M.B.A. from Columbia Business School. James is currently Chairman of BalletNext, a performing arts company in New York City.